Chimera viruses can help the fight against lymphomas

September 15, 2017, Instituto de Medicina Molecular
Mice spleen cells (blue) infected with the chimera kaposi virus showing the LANA protein (red). Credit: Pedro Simas Lab, iMM Lisboa

Researchers from Instituto de Medicina Molecular (iMM) Lisboa have created a chimera virus that allows the study of molecules to treat cancers caused by human herpes virus infection in mice models of disease.

There are several types of herpes able to infect humans, such as herpes simplex, chickenpox, cytomegalovirus, Epstein-Barr and Kaposi sarcoma herpesvirus. One of the main characteristics of herpesviruses is their ability to infect their hosts for life, and in a small percentage of these people, the development of cancer.

Cancers associated with Kaposi virus infection have an Achilles heel: Cell viability is directly dependent on the survival of the virus, which means that if the virus were eliminated, cancer cells would no longer proliferate, hence, the cancer would be cured.

In collaboration with a team from Harvard Medical School, researchers led by Pedro Simas (iMM) and Kenneth Kaye (Harvard) studied a protein of the Kaposi virus vital for maintaining infection. Without this protein, called LANA, the virus loses its ability to cause .

The team found that when LANA is cloned into a virus similar to Kaposi, but which infects mice instead of humans, it preserves its functionality. This finding came as a surprise, since it was assumed that as a consequence of the evolutionary divergence between human and other animal viruses, the genes that code for LANA could not be switched.

However, the work now published in Plos Pathogens showed that LANA's functional mechanisms are preserved even though there are more than 60 million years of evolutionary divergence between the human Kaposi sarcoma herpesvirus and its rodent homologue.

These findings allowed researchers to create a chimera virus—a mouse virus with a human viral gene that can be used to test molecules that inhibit human LANA protein in an animal model of disease, treating not only human but also its associated cancers. These molecules could hopefully be used in the future as drugs to treat Kaposi virus-associated lymphomas.

"In addition to Kaposi virus, the same experimental strategy to create chimera viruses, previously thought to be theoretically nonviable, can now be used for other viruses that use proteins similar to LANA, such as the Epstein-Barr virus, which infects greater than 90 percent of the world population or the human papillomavirus responsible for cervical cancers," said Pedro Simas.

Explore further: New infections cause dormant viruses to reactivate

More information: Aline C. Habison et al, Cross-species conservation of episome maintenance provides a basis for in vivo investigation of Kaposi's sarcoma herpesvirus LANA, PLOS Pathogens (2017). DOI: 10.1371/journal.ppat.1006555

Related Stories

New infections cause dormant viruses to reactivate

July 31, 2014
The famous slogan is "A diamond is forever," but that phrase might be better suited to herpes: Unlike most viruses, which succumb to the immune system's attack, herpes remains in the body forever, lying in wait, sometimes ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

Scientists identify possible key in virus, cancer research

August 27, 2015
Florida State University researchers have taken a big step forward in the fight against cancer with a discovery that could open up the door for new research and treatment options.

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.